RAPTライブシグナル | Getagraph.comで利益を最大化

売る 108178 min ago

@ $24.99

発行日: 14 2月 2024 @ 05:43

リターン: -67.59%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: 0.73 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	294 633
平均出来高	1.35M
時価総額	281.86M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.780 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.66
ATR14	$0.0110 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Robbins Wendye	Buy	6 925	Stock Option (right to buy)
2024-03-28	Gray Mary Ann	Buy	8 574	Stock Option (right to buy)
2024-03-28	Rieflin William Jl	Buy	11 871	Stock Option (right to buy)
2024-01-31	Ho William	Buy	75 000	Employee Stock Option (right to buy)
2024-01-31	Young Rodney Kb	Buy	90 000	Employee Stock Option (right to buy)

INSIDER POWER
94.05
Last 100 transactions
Buy: 3 742 359 \| Sell: 63 895

ボリューム相関

長: -0.07 (neutral)

短: -0.76 (moderate negative)

Signal:(31.973) Neutral

Rapt Therapeutics Inc 相関

10 最も正の相関
RDUS	0.903
ICON	0.901
ATCX	0.9
SYKE	0.898
PAE	0.889
BRACU	0.886
RCON	0.884
CLBT	0.884
ABNB	0.878
DKNG	0.876

10 最も負の相関
VIEW	-0.886
SBBP	-0.863
TUEM	-0.855
LGHL	-0.855
ARDS	-0.848
LCAP	-0.844
RPTX	-0.839
AHPI	-0.839
MTEX	-0.838
NAKD	-0.838

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Rapt Therapeutics Inc 相関 - 通貨/商品

-0.58
( weak negative )

-0.62
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.25
( neutral )

Rapt Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
収益:	$0
総利益:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
収益:	$1.53M
総利益:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
収益:	$3.81M
総利益:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.